DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors

Information source: The University of Texas Health Science Center at Tyler
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Breast Cancer

Intervention: Celecoxib (Drug); Placebo (Drug); Cholecalciferol (Drug)

Phase: Phase 1/Phase 2

Status: Recruiting

Sponsored by: The University of Texas Health Science Center at Tyler

Official(s) and/or principal investigator(s):
Edward Sauter, MD, PhD, Principal Investigator, Affiliation: University of North Dakota

Overall contact:
Edward Sauter, MD, PhD, Phone: 701-777-2284, Email: edward.sauter@med.und.edu

Summary

This is a biomarker study with the goal of measuring changes in proteins and gene methylation. This study is not intended for use in diagnosing, mitigating, treating, curing, or preventing disease. The purpose of this study is to determine if Vitamin D (cholecalciferol) alone and in combination with celecoxib (Celebrex, a non-steroidal anti-inflammatory drug, or NSAID), to decrease breast cancer risk by their effect on certain biological indicators (biomarkers) of breast cancer risk (called PGE2, COX-2, and 15-PGDH) and cell changes in the breast.

Clinical Details

Official title: Breast Cancer Prevention Using Synergistic Prostaglandin Inhibitors (The Vitamin D/Celecoxib Study)

Study design: Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Primary outcome: PG synthesis and metabolism

Secondary outcome:

Proliferative activity in the breast, as measured by MD cell morphology

Circulating levels of 25(OH)D, 1,25(OH)2D, and celecoxib

Detailed description: This is a biomarker study with the goal of measuring changes in protein and RNA expression. This study is not intended for use in diagnosing, mitigating, treating, curing, or preventing disease. 66 women at high risk for breast cancer (gail risk >/= 1. 66% for 5 year risk, or personal or family history)will be recruited and enrolled. 22 women will be randomized into each arm, with anticipation of 2 women in each group will not be evaluable, leaving 20 in each group for evaluation. A combination of vitamin D and celecoxib act synergistically to decrease breast cancer risk by decreasing cell proliferation in the mammary epithelium through their action on prostaglandin synthesis and metabolism. Specific Aims: In women at increased breast cancer risk, determine the effect of vitamin D, with or without celecoxib, on 1. PG synthesis and metabolism, through the measurement of 15-PGDH, COX-2, and PGE2 in the breast Rationale: 1,25(OH)2D, the active form of vitamin D, has been shown in vitro to decrease PGE2 both by interfering with its production and by increasing its breakdown, leading to lower cell proliferation. Celecoxib potentiated the antiproliferative effect, allowing a much lower dose of each agent when used in combination than in isolation. 2. Proliferative activity in the breast, as measured by Mammary Ductoscopy (MD) cell morphology Rationale: Both MD and Nipple Aspirate Fluid (NAF) contain ductal epithelial cells, but MD samples contain more cells for cytologic review than NAF. Findings on MD cytology correlate with likelihood of breast cancer (2), NAF cytology relates to breast cancer risk and improves risk stratification (3), and bioactive food components can alter NAF cytology (4). 3. Circulating levels of 25(OH)D, 1,25(OH)2D, and celecoxib, and determine if the levels of these compounds correlate with response to markers of PG synthesis and metabolism or cell proliferation.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Women 18 years of age or older

- Increased risk for breast cancer (demonstrated by strong family history [one 1st

degree or two 2nd degree relatives], history of DCIS, IBC, or precancerous changes in breasts). OR Gail Model risk of developing IBC in a 5-year period of >1. 66%

- Women with a history of breast cancer, must be free of disease and finished with

treatment

- ECOG Performance Status score 0-1

- Premenopausal women must not be pregnant.

Exclusion Criteria:

- History of bilateral mastectomy, or bilateral breast irradiation

- Significant medical or psychiatric problems making the participant a poor candidate

- Evidence of excess use of narcotics or drug dependency

- Have been pregnant and lactating in the past 2 years

- Significant history of peptic ulcer disease or upper gastrointestinal bleeding

- History of severe congestive heart failure that requires hospitalization or

intervention

- History of asthma requiring medication for treatment

- Allergy to sulfonamides or NSAID medications

- History of myocardial infarction or stroke

- Currently on Coumadin

- Currently on Tamoxifen (nolvadex),Evista (raloxifene), Femara (letrozole), Arimidex

(anastrozole), or Aromasin (exemestane)

- Undergone prior subaeolar breast surgery

Locations and Contacts

Edward Sauter, MD, PhD, Phone: 701-777-2284, Email: edward.sauter@med.und.edu

University of North Dakota, Grand Forks, North Dakota 58203, United States; Recruiting
Edward Sauter, MD, PhD, Phone: 701-777-2284, Email: edward.sauter@med.und.edu
Edward Sauter, MD, PhD, Principal Investigator
Robert Sticca, MD, Sub-Investigator
Additional Information

Starting date: July 2008
Last updated: December 19, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017